Hepatitis C Information Central


Discover the latest news about Hepatitis C infection, diagnosis, symptoms and treatments here at Hepatitis-Central.com.

Hep C information

News, Updates and Commentary

Free Newsletter
Hepatitis C Newsletter
We value your privacy. We will not rent your email to anyone.

HEPATITIS NEWS
The top stories compiled from over 5,500 sources, updated every 15 minutes

77 more hepatitis cases may trace to clinic, officials say
LAS VEGAS --Seventy-seven more people who were treated at a Las Vegas outpatient clinic have been diagnosed with hepatitis C, health officials said. Authorities can't say for sure how the 77 people were infected, said Brian Labus, senior epidemiologist

77 more hepatitis cases may trace to clinic
LAS VEGAS (AP) - Health officials in Las Vegas say 77 more people who were treated at an outpatient clinic have been diagnosed with hepatitis C. Authorities can't say for sure how the 77 people were infected. Officials say they know each was treated from


UPDATES AND COMMENTARY RSS Feed

Highly Effective Against HCV Genotype 1
When tested on people with Hepatitis C genotype 1, R7128 proved to be an effective addition to combination therapy after just four weeks' time. In addition to its anti-viral effect, polymerase inhibitor R7128 received good marks for safety and minimal...

Investigational Drug Beats Standard Therapy in Hepatitis C Study
A Phase IIa trial investigating triple combination therapy with PEGASYS, COPEGUS and Roche's investigational drug R1626, demonstrated a higher response rate than traditional combination therapy alone. While R1626's effectiveness and high barrier to resistance makes it a top Hepatitis C...

Hepatitis C Complications Helped by Maintenance Interferon
A four-year study confirms that low-dosage maintenance interferon therapy prevents disease progression in those with portal hypertension or cirrhosis from Hepatitis C....

J Rheumatol 1998 Jun;25(6):1115-1117

Ribavirin in Hepatitis C related cryoglobulinemia.

Durand JM, Cacoub P, Lunel-Fabiani F, Cosserat J, Cretel E, Kaplanski G, Frances C, Bletry O, Soubeyrand J, Godeau P

Department of Internal Medicine, CHU Sainte Marguerite, Marseille, France.

OBJECTIVE:

An open, uncontrolled trial of ribavirin, an oral guanosine nucleoside analog for treatment of Hepatitis C, in patients with Hepatitis C virus (HCV) associated cryoglobulinemia intolerant to interferon.

METHODS:

Five patients with cryoglobulinemia related to HCV infection unresponsive to interferon therapy received oral ribavirin (100 to 1200 mg daily) for 10 to 36 months.

RESULTS:

Patients treated with ribavirin had prompt decrease in serum aminotransferase levels and marked improvement of manifestations of cryoglobulinemia within a few weeks. Ribavirin did not eradicate HCV RNA from the sera, but a decrease in viral load was observed in 3 patients, from 232 to 86 x 10(5) copies HCV/ml. Relapse occurred within 3 months once therapy was discontinued. The drug was well tolerated, but mild dose related hemolysis was common.

CONCLUSION:

Ribavirin monotherapy may be effective in patients with symptomatic cryoglobulinemia related to HCV infection, but this effect is not sustained when ribavirin therapy is discontinued.

PMID: 9632073, UI: 98293834

  Hep C information

Information at this website is for educational purposes only; statements about products and health conditions
have not been evaluated by the U.S. Food & Drug Administration.

©1994-2008 Hepatitis-Central.com
Updated 12 May 2008